Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript

What happened: Cosmo N.V. (CMOPF) reported positive Phase 2 results for its topically acting rifamycin 1% gel in ulcerative colitis and proctitis, and held a call to discuss the data and differentiation. Key numbers: 45% of patients reached clinical remission versus 18% on placebo in the Phase 2 study. The call was held October 19, 2026. Why it matters: The company said the gel delivers an antibiotic directly where the disease is located and could become the first antibiotic in this indication. Professors David Rubin and Simon Travis joined to put the results in clinical context.

Cosmo N.V. (CMOPF) reported positive Phase 2 results for its topically acting rifamycin 1% gel in ulcerative colitis and proctitis, and held a call to discuss the data and differentiation.

The company said the gel delivers an antibiotic directly where the disease is located and could become the first antibiotic in this indication. Professors David Rubin and Simon Travis joined to put the results in clinical context.